Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extendedspectrum beta-lactamase- producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies

Infection

Volumn 40, Issue 6, 2012, Pages 613-619

  Liss, B J ^a   Vehreschild, J J ^a   Cornely, O A ^a,b   Hallek, M ^a   Fatkenheuer G ^a   Wisplinghoff, H ^a   Seifert, H ^a   Vehreschild, M J G T ^a,c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Bacteraemia; Blood cultures; Enterobacteriaceae; Extended spectrum beta lactamase; Febrile neutropenia; Intestinal colonisation; Vancomycin resistant enterococci

Indexed keywords

ALKYLATING AGENT; AMINOGLYCOSIDE; ANTHRACYCLINE; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEFTRIAXONE PLUS GENTAMICIN; CEPHALOSPORIN DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; LINEZOLID; MEROPENEM; METHOTREXATE; MITOXANTRONE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; PLATINUM DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BACTERIAL COLONIZATION; BLOOD CULTURE; BLOODSTREAM INFECTION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEBRILE NEUTROPENIA; FECES ANALYSIS; FEMALE; GERMANY; HUMAN; INTESTINE FLORA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MORTALITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PROSPECTIVE STUDY; RISK FACTOR; TERTIARY HEALTH CARE; TREATMENT DURATION; TREATMENT RESPONSE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; COHORT STUDIES; CROSS INFECTION; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FECES; FEMALE; GASTROINTESTINAL TRACT; GERMANY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS; VANCOMYCIN; VANCOMYCIN RESISTANCE; YOUNG ADULT;

EID: 84874106032     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-012-0269-y     Document Type: Article

References (28)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328-40.
2. Wisplinghoff H, Cornely OA, Moser S, et al. Outcomes of nosocomial bloodstream infections in adult neutropenic patients: a prospective cohort and matched case-control study. Infect Control Hosp Epidemiol. 2003;24:905-11.
3. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill. 2008;13.pii:19044.
4. Soderblom T, Aspevall O, Erntell M, et al. Alarming spread of vancomycin resistant enterococci in Sweden since 2007. Euro Surveill. 2010;15.pii:19620.
5. Blijlevens NM, Donnelly JP, De Pauw BE. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transpl. 2000;25:1269-78.
6. Ubeda C, Taur Y, Jenq RR, et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest. 2010;120:4332-41.
7. Cornely OA, Schirmacher P. Clinical picture: bacterial translocation in neutropenic sepsis. Lancet. 2001;358:1842.
8. Mauch H. MiQ: mikrobiologisch-infektiologische Qualitätsstandards in der mikrobiologischen-infektiologischen Diagnostik. Stuttgart: G Fischer; 2007.
9. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. Twenty-first informational supplement, M100-S21. Wayne, PA; 2011.
10. Vehreschild JJ, Rüping MJ, Wisplinghoff H, et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother. 2010;65:1466-71.
11. Reddy P, Malczynski M, Obias A, et al. Screening for extendedspectrum beta-lactamase-producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin Infect Dis. 2007;45:846-52.
12. Friedmann R, Raveh D, Zartzer E, et al. Prospective evaluation of colonization with extended-spectrum beta-lactamase (ESBL)-producing enterobacteriaceae among patients at hospital admission and of subsequent colonization with ESBL-producing enterobacteriaceae among patients during hospitalization. Infect Control Hosp Epidemiol. 2009;30:534-42.
13. Arnan M, Gudiol C, Calatayud L, et al. Risk factors for, and clinical relevance of, faecal extended-spectrum beta-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis. 2011;30:355-60.
14. Geser N, Stephan R, Hächler H. Occurrence and characteristics of extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae in food producing animals, minced meat and raw milk. BMC Vet Res. 2012;8:21.
15. Rhee MS, Lee SY, Hillers VN, McCurdy SM, Kang DH. Evaluation of consumer-style cooking methods for reduction of Escherichia coli O157:H7 in ground beef. J Food Prot. 2003;66:1030-4.
16. Stringer SC, George SM, Peck MW. Thermal inactivation of Escherichia coli O157:H7. Symp Ser Soc Appl Microbiol. 2000;29:79S-89S.
17. Melzer M, Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect. 2007;55:254-9.
18. Auerbach U. Epidemiologische Untersuchung zum Auftreten Glykopeptid-resistenter Enterokokken in einer Normalpopulation und bei definierten Patientengruppen. Inaugural-Dissertation zur Erlangung der Doktorwürde der Hohen Medizinischen Fakultät zu Kö ln. Köln. Universität zu Köln, 2002;118
19. Matar MJ, Tarrand J, Raad I, Rolston KV. Colonization and infection with vancomycin-resistant Enterococcus among patients with cancer. Am J Infect Control. 2006;34:534-6.
20. Weinstock DM, Conlon M, Iovino C, et al. Colonization, bloodstream infection, and mortality caused by vancomycinresistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transpl. 2007;13:615-21.
21. Kamboj M, Chung D, Seo SK, et al. The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transpl. 2010;16:1576-81.
22. Schuster F, Graubner UB, Schmid I, Weiss M, Belohradsky BH. Vancomycin-resistant-enterococci-colonization of 24 patients on a pediatric oncology unit. Klin Padiatr. 1998;210:261-3.
23. Moulin F, Dumontier S, Saulnier P, et al. Surveillance of intestinal colonization and of infection by vancomycin-resistant enterococci in hospitalized cancer patients. Clin Microbiol Infect. 1996;2:192-201.
24. Bossaer JB, Hall PD, Garrett-Mayer E. Incidence of vancomycinresistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Support Care Cancer. 2010;19:231-7.
25. Zaas AK, Song X, Tucker P, Perl TM. Risk factors for development of vancomycin-resistant enterococcal bloodstream infection in patients with cancer who are colonized with vancomycin-resistant enterococci. Clin Infect Dis. 2002;35:1139-46.
26. Padiglione AA, Wolfe R, Grabsch EA, et al. Risk factors for new detection of vancomycin-resistant enterococci in acute-care hospitals that employ strict infection control procedures. Antimicrob Agents Chemother. 2003;47:2492-8.
27. Kosack A, Riedel E, Kiehn TE, Small TN, Wexler LH, Dunkel IJ. Vancomycin-resistant enterococcus in pediatric oncology patients: an analysis of potential consequences of colonization and infection. Pediatr Blood Cancer. 2009;52:300-2.
28. Avery R, Kalaycio M, Pohlman B, et al. Early vancomycinresistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transpl. 2005;35:497-9.